DEA Places New Anesthetic Cipepofol in Schedule IV — What Registrants Need to Know

On August 27, 2026, the DEA published an interim final rule placing cipepofol — brand name Cypsedo — into Schedule IV of the CSA. The rule took effect immediately upon publication, which means every DEA registrant who intends to handle this drug is already subject to Schedule IV obligations, whether or not they've had time to update their compliance program.

If your pharmacy, distributor, or health system anticipates stocking Cypsedo once it reaches the U.S. market, here's what the rule actually requires — and where DEA left the door open for comment.

Background

Cipepofol is an intravenous general anesthetic, FDA-approved on May 29, 2026, for induction of general anesthesia in adults undergoing surgery. It's formulated as a 2.5 mg/mL emulsion in 20 mL single-use vials. Pharmacologically, it uses the same mechanism that put propofol and fospropofol in Schedule IV.

DEA didn't reach this decision on its own initiative. HHS submitted a scientific and medical evaluation along with a formal scheduling recommendation on May 6, 2026, and DEA's independent eight-factor analysis concurred: low abuse potential relative to Schedule III substances, an accepted medical use, and a risk of limited physical or psychological dependence consistent with the other drugs in Schedule IV.

Why an Interim Final Rule — No Notice and Comment First

This is worth flagging for clients who are used to seeing DEA scheduling actions go through full notice-and-comment rulemaking. DEA issued this one as an interim final rule under the Improving Regulatory Transparency for New Medical Therapies Act, 21 U.S.C. § 811(j), which requires expedited scheduling — within 90 days of an HHS recommendation — for a newly FDA-approved drug with abuse potential. That statute lets DEA schedule first and take comments after.

Practically, that means the Schedule IV requirements below are already binding. The rule includes a 32-day comment period, closing September 28, 2026, and interested parties may also request a hearing (with a written statement of position) by that same deadline. But absent a successful challenge, this placement is not going to change before it takes effect — because it already has.

The Compliance Obligations, in Plain Terms

Once Cypsedo is available domestically, anyone who manufactures, distributes, reverse distributes, dispenses, imports, exports, conducts research with, or otherwise possesses it needs a DEA registration. For registrants already handling Schedule III–V controlled substances, the incremental lift here is manageable.

My Read

The abuse potential here is less than DEA's typical Schedule IV analysis: cipepofol has only been marketed in China since 2021 and DEA's own NFLIS-Drug database shows it entirely absent from the illicit U.S. market. The scheduling decision leans heavily on the propofol comparison rather than any documented domestic diversion. For registrants, though, the practical question isn't whether the classification is right—it's whether your security, inventory, recordkeeping, and prescribing systems are already built to absorb a new Schedule IV product on day one of availability. For most pharmacies and distributors already handling other Schedule IV anesthetics, this should be a system/process update rather than a structural change.

If you have questions about how this rule affects your registration, security plan, or recordkeeping obligations reach out to DeKo Law LLC.

This post is for general informational purposes and does not constitute legal advice. Consult counsel regarding your specific compliance obligations.